United Capital Financial Advisors’s Invesco Biotechnology & Genome ETF PBE Stock Holding History
Bought
Maintained
Sold
Other funds holding PBE
GKWIM
YIA
United Capital Financial Advisors's PBE Position: Q1 2026 in Review
United Capital Financial Advisors reduced its Invesco Biotechnology & Genome ETF (PBE) stake by 0.22% in Q1 2026, selling an estimated $17.9K and leaving 101,985 shares worth $8.08M. The position accounts for 0.05% of the portfolio, ranked #271.
United Capital Financial Advisors first reported a position in PBE in Q4 2017 and has held it in 19 quarters since. The position peaked at $8.4M in Q4 2025. 100 funds tracked by Wall St. Rank hold PBE as of Q1 2026.
- United Capital Financial Advisors held 101,985 shares of Invesco Biotechnology & Genome ETF worth $8.08M as of Q1 2026.
- United Capital Financial Advisors sold 222 Invesco Biotechnology & Genome ETF shares in Q1 2026, an estimated $17.9K.
- Invesco Biotechnology & Genome ETF made up 0.05% of United Capital Financial Advisors's portfolio in Q1 2026, its #271 holding.
- United Capital Financial Advisors first reported a position in Invesco Biotechnology & Genome ETF in Q4 2017 and has held it in 19 quarters since.
- United Capital Financial Advisors's Invesco Biotechnology & Genome ETF position peaked at $8.4M in Q4 2025.
- 100 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2026.
Based on United Capital Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.